Immune checkpoint modulators leading the way in gastric cancer
Gastric cancer is an area of extreme unmet need where immuno-oncology (I-O) treatments could provide a better survival outcome to patients.
Merck & Co (NYSE: MRK) and two company partnerships, Bristol-Myers Squibb (NYSE: BMY)/Ono Pharmaceuticals (TYO: 4528) and Merck KGaA (MRK: DE)/EMD Serono/Pfizer (NYSE: PFE), are leading the development of immune checkpoint modulators in gastric cancer.
According to analytics company GlobalData, among the 14 Phase II/III and III trials in gastric cancer assessing immune checkpoint modulators, eight are part of currently ongoing trials exploring the potential of immune checkpoint inhibitors in combination with either standard of care chemotherapy or other I-O agents. GlobalData expects this strategy to be practice changing for gastric cancer patients over the next three years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze